Evidence map›Paper›PMID 35490159›Full record

ArticleScientific reports2022

Revisiting the standard for modeling the spread of infectious diseases.

Michael Nikolaou

Abstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Michael NikolaouChemical and Biomolecular Engineering Department, University of Houston, 4226 MLK Blvd, Houston, TX, 77204-4004, USA. Nikolaou@uh.edu.ORCID 0000-0003-0241-6600

Funding

Personalized Antimicrobial Combinations to Combat ResistanceR01AI140287 · NIAID · UNIVERSITY OF HOUSTON · PI VINCENT H TAM · 2018 to 2026
$5.9M
NIAID NIH HHS R01 AI140287NIH HHS R01AI140287
6 · The paper itself

Abstract

The COVID-19 epidemic brought to the forefront the value of mathematical modelling for infectious diseases as a guide to help manage a formidable challenge for human health. A standard dynamic model widely used for a spreading epidemic separates a population into compartments-each comprising individuals at a similar stage before, during, or after infection-and keeps track of the population fraction in each compartment over time, by balancing compartment loading, discharge, and accumulation rates. The standard model provides valuable insight into when an epidemic spreads or what fraction of a population will have been infected by the epidemic's end. A subtle issue, however, with that model, is that it may misrepresent the peak of the infectious fraction of a population, the time to reach that peak, or the rate at which an epidemic spreads. This may compromise the model's usability for tasks such as "Flattening the Curve" or other interventions for epidemic management. Here we develop an extension of the standard model's structure, which retains the simplicity and insights of the standard model while avoiding the misrepresentation issues mentioned above. The proposed model relies on replacing a module of the standard model by a module resulting from Padé approximation in the Laplace domain. The Padé-approximation module would also be suitable for incorporation in the wide array of standard model variants used in epidemiology. This warrants a re-examination of the subject and could potentially impact model-based management of epidemics, development of software tools for practicing epidemiologists, and related educational resources.

Indexed as

Communicable DiseasesCOVID-19EpidemicsHumansModels, Theoretical

Identifiers

PMID35490159
PMCPMC9056532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.